Novavax, a pharmaceutical firm that created a Covid vaccine, has agreed to resolve a Class Action lawsuit and establish a $47,000,000 fund to pay back ...
Novavax's updated protein-based non-mRNA COVID-19 vaccine will be available in Canada for individuals aged 12 and older in the coming ...
Updated Sarah BranerThe premier global health authority has given Novavax’s updated COVID-19 shot a stamp of approval.The ...
Novavax (NASDAQ:NVAX) has agreed to settle a securities class action over its COVID-19 vaccine claims for $47M. The lawsuit was filed in 2021 by Sothinathan Sinnathurai in the U.S. District Court of ...
A lot has changed with COVID-19 vaccines since they first debuted back in December 2020. We’ve seen a few hit the market, one ...
Listen to this article Gaithersburg-based Novavax Inc. Tuesday announced its Nuvaxovid XBB.1.5 COVID-19 vaccine (NVX-CoV2601) ...
"The WHO Emergency Use Listing of our updated protein-based non-mRNA COVID-19 vaccine enables expedited regulatory approvals for its 194 member states and UN procurement agencies, such as UNICEF, ...
FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants - ...
Health Canada has authorized an adapted vaccine from Novavax to prevent COVID-19 in people age 12 and older.The vaccine uses ...
In this radio interview with John Batchelor, our conversation includes (1) the approval of the latest COVID vaccines; and (2) ...
Past doses of the COVID vaccine will not protect you against the current strains. Current available vaccines include ...
Novavax Inc (NASDAQ:NVAX) reported total revenue of $187 million for Q3 2023, a significant decrease from $735 million in the same period in 2022. The company reduced operating expenses by $950 ...
